Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6987) 6987
Book Review (2032) 2032
Publication (651) 651
Book Chapter (61) 61
Conference Proceeding (33) 33
Magazine Article (8) 8
Dissertation (7) 7
Reference (5) 5
Book / eBook (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5951) 5951
humans (4381) 4381
glucagon-like peptide-1 (3751) 3751
animals (3052) 3052
male (2569) 2569
endocrinology & metabolism (2299) 2299
diabetes mellitus, type 2 - drug therapy (1849) 1849
diabetes (1804) 1804
type 2 diabetes (1689) 1689
female (1571) 1571
glucagon (1549) 1549
glucose (1521) 1521
insulin (1419) 1419
hypoglycemic agents - therapeutic use (1347) 1347
peptides (1264) 1264
mice (1220) 1220
liraglutide (1204) 1204
glucagon-like peptide 1 (1181) 1181
glp-1 (1173) 1173
rats (1146) 1146
glucagon-like peptide 1 - analogs & derivatives (1139) 1139
pharmacology & pharmacy (1085) 1085
middle aged (1015) 1015
obesity (931) 931
adult (918) 918
blood glucose - metabolism (863) 863
glucagon-like peptide-1 receptor (828) 828
glycemic control (778) 778
glucagon-like peptide 1 - therapeutic use (749) 749
glucagon-like peptide 1 - metabolism (729) 729
diabetes mellitus (728) 728
insulin - metabolism (710) 710
hypoglycemic agents - pharmacology (705) 705
analysis (698) 698
research (681) 681
abridged index medicus (675) 675
exenatide (665) 665
physiological aspects (659) 659
dextrose (614) 614
glucagon-like peptide 1 - pharmacology (606) 606
peptides - pharmacology (606) 606
diabetes mellitus, type 2 - blood (598) 598
aged (590) 590
secretion (587) 587
treatment outcome (584) 584
physiology (583) 583
rodents (580) 580
diabetes mellitus, type 2 - metabolism (568) 568
insulin secretion (564) 564
hypoglycemic agents - administration & dosage (551) 551
blood glucose - drug effects (548) 548
care and treatment (548) 548
insulin - blood (539) 539
internal medicine (537) 537
food-intake (534) 534
biochemistry & molecular biology (525) 525
insulin resistance (521) 521
peptides - therapeutic use (517) 517
health aspects (515) 515
exendin-4 (513) 513
digestive, oral, and skin physiology (511) 511
type-2 diabetes-mellitus (505) 505
glucagon-like peptide 1 - blood (495) 495
medicine & public health (493) 493
beta-cell function (480) 480
hypoglycemic agents - adverse effects (478) 478
endocrine system (470) 470
metabolism (463) 463
receptors, glucagon - agonists (455) 455
drug therapy (454) 454
hypoglycemic agents (449) 449
diabetes therapy (443) 443
metformin (440) 440
dipeptidyl-peptidase iv inhibitors - therapeutic use (439) 439
double-blind (432) 432
insulin-secretion (423) 423
venoms - pharmacology (421) 421
expression (416) 416
receptor (416) 416
mice, inbred c57bl (409) 409
body weight (406) 406
hyperglycemia (404) 404
glucose metabolism (403) 403
risk factors (400) 400
hormones (387) 387
venoms - therapeutic use (383) 383
hormones, hormone substitutes, and hormone antagonists (382) 382
gastric-inhibitory polypeptide (381) 381
article (376) 376
nutrition & dietetics (371) 371
rats, sprague-dawley (370) 370
incretin (369) 369
receptors, glucagon - metabolism (364) 364
glucagon-like peptide 1 - administration & dosage (354) 354
dose-response relationship, drug (338) 338
appetite (336) 336
dependent insulinotropic polypeptide (336) 336
insulin-secreting cells - metabolism (334) 334
double-blind method (331) 331
drug therapy, combination (331) 331
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6842) 6842
German (44) 44
Spanish (24) 24
Japanese (22) 22
French (18) 18
Chinese (15) 15
Danish (8) 8
Italian (8) 8
Korean (8) 8
Czech (7) 7
Polish (7) 7
Hungarian (5) 5
Russian (4) 4
Portuguese (3) 3
Swedish (3) 3
Croatian (2) 2
Dutch (2) 2
Bosnian (1) 1
Norwegian (1) 1
Romanian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text A Potent α/β-Peptide Analogue of GLP-1 with Prolonged Action in Vivo
by Johnson, Lisa M and Barrick, Stacey and Hager, Marlies V and McFedries, Amanda and Homan, Edwin A and Rabaglia, Mary E and Keller, Mark P and Attie, Alan D and Saghatelian, Alan and Bisello, Alessandro and Gellman, Samuel H
Journal of the American Chemical Society, ISSN 0002-7863, 09/2015, Volume 136, Issue 37, pp. 12848 - 12851
Glucagon-like peptide-1 (GLP-1) is a natural agonist for GLP-1R, a G protein-coupled receptor (GPCR) on the surface of pancreatic beta cells. GLP-1R agoinsts... 
BH3 HELIX | DESIGN | INHIBITION | GLUCAGON-LIKE PEPTIDE-1 | STABILITY | BIOLOGICAL-ACTIVITY | PROTEIN-PROTEIN INTERACTIONS | COUPLED RECEPTORS | AMINO-ACID RESIDUES | CHEMISTRY, MULTIDISCIPLINARY | HELIX MIMICRY | Receptors, Glucagon - agonists | Amino Acid Sequence | Glucagon-Like Peptide 1 - metabolism | Glucagon-Like Peptide 1 - analogs & derivatives | Humans | Cells, Cultured | Glucagon-Like Peptide 1 - pharmacology | Molecular Sequence Data | Glucagon-Like Peptide 1 - chemistry | Animals | Glucagon-Like Peptide-1 Receptor | Mice | Protein Stability | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Care and treatment | Peptides | Glucagon | Analysis | Index Medicus | Residues | Surgical implants | Biomedical materials | In vivo testing | Surface chemistry | In vivo tests | Biocompatibility | Strategy | Communication
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment
by Chodorge, Matthieu and Celeste, Anthony J and Grimsby, Joseph and Konkar, Anish and Davidsson, Pia and Fairman, David and Jenkinson, Lesley and Naylor, Jacqueline and White, Nicholas and Seaman, Jonathan C and Dickson, Karen and Kemp, Benjamin and Spooner, Jennifer and Rossy, Emmanuel and Hornigold, David C and Trevaskis, James L and Bond, Nicholas J and London, Timothy B and Buchanan, Andrew and Vaughan, Tristan and Rondinone, Cristina M and Osbourn, Jane K
Scientific Reports, ISSN 2045-2322, 12/2018, Volume 8, Issue 1, pp. 17545 - 14
Type 2 diabetes (T2D) is a complex and progressive disease requiring polypharmacy to manage hyperglycaemia and cardiovascular risk factors. However, most... 
DENSITY-LIPOPROTEIN CHOLESTEROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | MULTIDISCIPLINARY SCIENCES | IN-VIVO | REDUCES LDL-CHOLESTEROL | RECEPTOR | STATIN | MONOCLONAL-ANTIBODY | MECHANISMS | HYPERCHOLESTEROLEMIA | Lipoproteins (low density) | Animal models | Peptides | Glucagon | Diabetes mellitus | Subtilisin | Risk factors | Cholesterol | Hyperglycemia | Kexin | Molecular modelling | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Glucagon-like peptide 1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice
by O'Harte, F.P.M and Ng, M.T and Lynch, A.M and Conlon, J.M and Flatt, P.R
Molecular and Cellular Endocrinology, ISSN 0303-7207, 08/2016, Volume 431, Issue C, pp. 133 - 144
The antidiabetic potential of thirteen novel dogfish glucagon derived analogues were assessed and in acute studies. Stable peptide analogues enhanced insulin... 
Glucagon-like peptide-1 (GLP-1) | Glucagon | Dogfish glucagon | Glucose dependent insulinotropic polypeptide (GIP) | Antidiabetic and antihyperglycaemic | Diabetes | Dual agonist | Acute effects | GLUCOSE-INTOLERANCE | EXENATIDE | CELL BIOLOGY | OBESITY | LIRAGLUTIDE | FUNCTIONAL EXPRESSION | ENDOCRINOLOGY & METABOLISM | DEGRADATION | GLP-1 RECEPTOR | GIP ANALOGS | ACTING PEPTIDE | POLYPEPTIDE | Cell Line | Cricetinae | Gastric Inhibitory Polypeptide - metabolism | Glucagon-Like Peptide 1 - metabolism | Humans | Mice, Inbred C57BL | Receptors, Glucagon - metabolism | Dogfish - metabolism | Male | Receptors, Gastrointestinal Hormone - metabolism | Hypoglycemic Agents - pharmacology | Mice, Knockout | Peptides - pharmacology | Insulin - metabolism | Insulin-Secreting Cells - metabolism | Animals | Insulin-Secreting Cells - drug effects | HEK293 Cells | Glucose - metabolism | Glucagon - metabolism | Mice | Insulin | Cyclic adenylic acid | Index Medicus | Receptors | Peptides | Dogfish | In vivo methods and tests | In vitro testing | Glucose
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Synthesis and Evaluation of Optical and PET GLP-1 Peptide Analogues for GLP-1R Imaging
by Azad, Babak Behnam and Rota, Vanessa and Yu, Lihai and Mcgirr, Rebecca and Amant, André H. St and Lee, Ting-Yim and Dhanvantari, Savita and Luyt, Leonard G
Molecular Imaging, ISSN 1535-3508, 1/2015, Volume 14, Issue 1, pp. 1 - 16
A fluorescein-GLP-1 (7-37) analog was generated to determine GLP-1R distribution in various cell types of the pancreas in both strains of mice and... 
GLP-1(9-36) AMIDE | GLUCAGON-LIKE PEPTIDE-1 | GLUCOSE | BETA-CELLS | BIOCHEMICAL RESEARCH METHODS | RECEPTOR ACTIVATION | RENAL UPTAKE | MONOCLONAL-ANTIBODY | MICE | INSULINOMAS | EXPRESSION | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Neoplasm Transplantation | Cricetinae | Gallium - chemistry | Cricetulus | Peptides - chemistry | Glucagon-Like Peptide 1 - analogs & derivatives | Mice, Inbred C57BL | Male | Molecular Imaging | Positron-Emission Tomography | Gallium Radioisotopes - chemistry | Glucagon-Like Peptide-1 Receptor - metabolism | Insulin - metabolism | Animals | Insulinoma - metabolism | Radioimmunoassay | Glucose - metabolism | Mice | Cyclic AMP - metabolism | Microscopy, Fluorescence | CHO Cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Glucagonlike peptide 1 analogs in diabetes care
by Lindblad, Adrienne J and Garrison, Scott and Allan, G. Michael
Canadian Family Physician, ISSN 0008-350X, 05/2017, Volume 63, Issue 5, pp. 371 - 371
MEDICINE, GENERAL & INTERNAL | PRIMARY HEALTH CARE | METAANALYSIS | LIRAGLUTIDE | CANCER | DRUGS | Glycated Hemoglobin A - analysis | Glucagon-Like Peptide 1 - analogs & derivatives | Glucagon-Like Peptides - administration & dosage | Humans | Cardiovascular Diseases - epidemiology | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Diabetes Mellitus, Type 2 - complications | Neoplasms - epidemiology | Randomized Controlled Trials as Topic | Prescription drugs | Clinical outcomes | Diabetes | Index Medicus | Practice
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. The novel use of peptide analogs in short bowel syndrome
by Jeppesen, Palle Bekker
Expert Review of Gastroenterology and Hepatology, ISSN 1747-4124, 2013, Volume 7, Issue 3, pp. 197 - 199
pathogesis | glucagon-like peptide 2 | intestinal failure | peptide analogs | short bowel syndrome | teduglutide | BRAKE | GLUCAGON-LIKE PEPTIDE-2 | MICE | ABSORPTION | GASTROENTEROLOGY & HEPATOLOGY | MOTILITY
Journal Article
Details down arrow
7. Full Text A novel long‐acting glucose‐dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents
by Tatarkiewicz, K and Hargrove, D. M and Jodka, C. M and Gedulin, B. R and Smith, P. A and Hoyt, J. A and Lwin, A and Collins, L and Mamedova, L and Levy, O. E and D'Souza, L and Janssen, S and Srivastava, V and Ghosh, S. S and Parkes, D. G
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2014, Volume 16, Issue 1, pp. 75 - 85
AimGlucose-dependent insulinotropic peptide (GIP) is an incretin hormone that is released from intestinal K cells in response to nutrient ingestion. We aimed... 
resistant | DPP‐IV | diabetes | Trp‐cage | rodents | GIP | Diabetes | DPP-IV resistant | Rodents | Trp-cage | RECEPTOR | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | BIOLOGICAL-ACTIVITY | IN-VIVO | ENDOCRINOLOGY & METABOLISM | GENE-EXPRESSION | SECRETION | GASTRIC-INHIBITORY POLYPEPTIDE | BINDING | Diabetes Mellitus, Experimental - drug therapy | Gastric Inhibitory Polypeptide - metabolism | Obesity - drug therapy | Gastric Inhibitory Polypeptide - drug effects | Rats | Male | Rats, Sprague-Dawley | Chemistry, Pharmaceutical | Gastric Inhibitory Polypeptide - chemical synthesis | Hypoglycemic Agents - pharmacology | Obesity - metabolism | Rats, Zucker | Animals | Incretins - pharmacology | Female | Mice, Obese | Mice | Blood Glucose - metabolism | Diabetes Mellitus, Experimental - metabolism | Gastric Inhibitory Polypeptide - pharmacology | Gastric Inhibitory Polypeptide - analogs & derivatives | Glucose metabolism | Peptides | Streptozocin | Physiological aspects | Glucose | Glucose tolerance tests | Dextrose | Studies | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Lipidation and conformational constraining for prolonging the effects of peptides: Xenopus glucagon-like peptide 1 analogues with potent and long-acting hypoglycemic activity
by Han, Jing and Huang, Yue and Chen, Xinyu and Zhou, Feng and Fei, Yingying and Fu, Junjie
European Journal of Pharmaceutical Sciences, ISSN 0928-0987, 10/2018, Volume 123, pp. 111 - 123
The main disadvantages of glucagon-like peptide 1 (GLP-1) are its rapid degradation and excretion. These bottlenecks can be overcome by lipidation or other... 
Type 2 diabetes | Conformational constrain | Lipidation | Glucagon-like peptide 1 | DESIGN | GLP-1 RECEPTOR AGONISTS | EFFICACY | SAFETY | PLASMA STABILITY | DISCOVERY | OBESITY | DISEASE | PHARMACOLOGY & PHARMACY | TYPE-2 DIABETES-MELLITUS | DERIVATIVES | Glycosylated hemoglobin | Glucagon | Analysis | Body weight
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys
by Thomsen, Morgane and Holst, Jens Juul and Molander, Anna and Linnet, Kristian and Ptito, Maurice and Fink-Jensen, Anders
Psychopharmacology, ISSN 0033-3158, 2/2019, Volume 236, Issue 2, pp. 603 - 611
Preclinical studies in rodents have demonstrated inhibitory effects of glucagon-like peptide-1 (GLP-1) receptor stimulation on alcohol consumption. The effects... 
Neurosciences | Biomedicine | Alcohol use disorder | GLP-1 | Non-human primate | Pharmacotherapy | Pharmacology/Toxicology | Psychiatry | Liraglutide | Exendin-4 | PSYCHIATRY | EXENATIDE EXTENDED-RELEASE | MEDIATED BEHAVIORS | RECEPTOR | NEUROSCIENCES | PHARMACOKINETICS | AGONIST EXENDIN-4 | PHARMACOLOGY & PHARMACY | GLP-1 ANALOG | USE DISORDERS | CONSUMPTION | FOOD | Water | Glucagon-Like Peptide 1 | Humans | Cercopithecus aethiops | Ethanol - administration & dosage | Exenatide - pharmacology | Male | Alcohol Drinking | Self Administration | Animals | Liraglutide - pharmacology | Central Nervous System Depressants - administration & dosage | Behavior, Animal - drug effects | Drinking - drug effects | Glucagon-Like Peptide-1 Receptor - agonists | Prevention | Physiological aspects | Peptide hormones | Alcoholism | Consumption | Drinking water | Peptides | Control methods | Glucagon | Drinking behavior | Alcohol | Stimulation | Monkeys | Monkeys & apes | Alcohol use | Studies | Vomiting | Rodents | Primates | Alcoholic beverages | Water intake | Titration | Water intakes | Plasma levels | Glucagon-like peptide 1 | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Biological activity of EXf, a peptide analogue of exendin-4
by Song, Guang-ming and Huan, Yi and Sun, Su-juan and Chen, Yue-teng and Liu, Quan and Shen, Zhu-fang
European Journal of Pharmacology, ISSN 0014-2999, 2010, Volume 628, Issue 1, pp. 261 - 267
Exendin-4 is an incretin mimetic that has been developed for the treatment of patients with type 2 diabetes. EXf is an available carboxy-terminal truncated... 
Glucose tolerance | Mice | Insulin | NIT-1 cells | Incretin mimetic | GLYCEMIC CONTROL | SULFONYLUREA | ANTAGONIST | EXENATIDE EXENDIN-4 | INSULIN-SECRETION | TREATED PATIENTS | GLUCAGON-LIKE PEPTIDE-1 | GLUCOSE | PHARMACOLOGY & PHARMACY | GLP-1 RECEPTOR | TYPE-2 DIABETES-MELLITUS | Transcription, Genetic - drug effects | Molecular Sequence Data | Male | Exenatide | Intestine, Small - physiology | Promoter Regions, Genetic - genetics | Base Sequence | Postprandial Period | Female | Cyclic AMP - genetics | Response Elements - genetics | Insulin - genetics | Insulin Secretion | Amino Acid Sequence | Cell Line | Fasting | Peptides - chemistry | Rats | Peptides - pharmacology | Pregnancy | Insulin - metabolism | Animals | Intestine, Small - drug effects | Venoms - chemistry | Blood Glucose - metabolism | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 diabetes
by Nauck, Michael A and Petrie, John R and Sesti, Giorgio and Mannucci, Edoardo and Courrèges, Jean-Pierre and Lindegaard, Marie L and Jensen, Christine B and Atkin, Stephen L and Study 1821 Investigators and for the Study 1821 Investigators
Diabetes Care, ISSN 0149-5992, 02/2016, Volume 39, Issue 2, pp. 231 - 241
OBJECTIVE To investigate the dose-response relationship of semaglutide versus placebo and open-label liraglutide in terms of glycemic control in patients with... 
ENERGY-INTAKE | RECEPTOR AGONISTS | PEPTIDE-1 | ENDOCRINOLOGY & METABOLISM | Glycated Hemoglobin A - analysis | Body Weight | Double-Blind Method | Drug Administration Schedule | Nausea - chemically induced | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Treatment Outcome | Blood Glucose - drug effects | Dose-Response Relationship, Drug | Glucagon-Like Peptides - adverse effects | Vomiting - chemically induced | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Liraglutide - therapeutic use | Adult | Female | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Usage | Care and treatment | Analysis | Clinical trials | Dosage and administration | Glycemic index | Liraglutide | Diabetes | Hypoglycemia | Medical treatment | Weight | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Rational design of dimeric lipidated Xenopus glucagon-like peptide 1 analogues as long-acting antihyperglycaemic agents
by Han, Jing and Huang, Yue and Chen, Xinyu and Zhou, Feng and Fei, Yingying and Fu, Junjie
European Journal of Medicinal Chemistry, ISSN 0223-5234, 09/2018, Volume 157, pp. 177 - 187
Dimerization is viewed as an effective means to enhance the binding affinity and therapeutic potency of peptides. Both dimerization and lipidation effectively... 
Type 2 diabetes | Lipidization | Dimerization | Glucagon-like peptide 1 | HALF-LIFE | CHEMISTRY, MEDICINAL | GLP-1 RECEPTOR AGONISTS | EXENDIN-4 | PROLONGS | BIOLOGICAL EVALUATION | DISCOVERY | THERAPEUTIC UTILITIES | Albumin | Hypoglycemic agents | Glucagon | Fatty acids | Analysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Neoglycolipids for Prolonging the Effects of Peptides: Self-Assembling Glucagon-like Peptide 1 Analogues with Albumin Binding Properties and Potent in Vivo Efficacy
by Van Witteloostuijn, Søren B and Mannerstedt, Karin and Wismann, Pernille and Bech, Esben M and Thygesen, Mikkel B and Vrang, Niels and Jelsing, Jacob and Jensen, Knud J and Pedersen, Søren L
Molecular Pharmaceutics, ISSN 1543-8384, 01/2017, Volume 14, Issue 1, pp. 193 - 205
Novel principles for optimizing the properties of peptide-based drugs are needed in order to leverage their full pharmacological potential. We present the... 
glycolipid | half-life extension | peptide | lipidation | glucagon-like peptide 1 | neoglycolipid | biopharmaceutical | HALF-LIFE | MEDICINE, RESEARCH & EXPERIMENTAL | PROTRACTION | GLP-1 RECEPTOR AGONISTS | MECHANISM | HUMAN INSULIN | LIRAGLUTIDE | ALTERNATIVES | PHARMACOLOGY & PHARMACY | ABSORPTION | DERIVATIVES | PEGYLATION | Glucagon-Like Peptide 1 - metabolism | Peptides - chemistry | Albumins - metabolism | Glucose Tolerance Test - methods | Delayed-Action Preparations - chemistry | Male | Hypoglycemic Agents - chemistry | Diabetes Mellitus, Type 2 - metabolism | Peptides - pharmacology | Insulin - metabolism | Animals | Delayed-Action Preparations - pharmacology | Glucose - metabolism | Glycolipids - blood | Mice | Homeostasis - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)
by Wysham, Carol and Blevins, Thomas and Arakaki, Richard and Colon, Gildred and Garcia, Pedro and Atisso, Charles and Kuhstoss, Debra and Lakshmanan, Mark
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells
by Shiraki, Aya and Oyama, Jun-ichi and Komoda, Hiroshi and Asaka, Machiko and Komatsu, Aiko and Sakuma, Masashi and Kodama, Kazuhisa and Sakamoto, Yoshiko and Kotooka, Norihiko and Hirase, Tetsuaki and Node, Koichi
Atherosclerosis, ISSN 0021-9150, 2012, Volume 221, Issue 2, pp. 375 - 382
Highlights ► Liraglutide can normalize TNF-α-induced pro-oxidant production in HUVEC probably through reduced expression of NADPH oxidase subunit gp91phox and... 
Cardiovascular | Oxidative stress | NF-κB | Endothelial cell | Inflammation | Apoptosis | CHRONIC HEART-FAILURE | TRANSLOCATION | PROTEIN-KINASE-C | PENTRAXIN 3 | ACTIVATION | CARDIAC & CARDIOVASCULAR SYSTEMS | IN-VITRO | NF-kappa B | ACUTE MYOCARDIAL-INFARCTION | DEGRADATION | PERIPHERAL VASCULAR DISEASE | DYSFUNCTION | VASCULAR NAD(P)H OXIDASE | Tumor Necrosis Factor-alpha - metabolism | Phosphorylation | Reactive Oxygen Species - metabolism | Human Umbilical Vein Endothelial Cells - metabolism | Membrane Glycoproteins - metabolism | Protein Kinase C-alpha - metabolism | Apoptosis - drug effects | Humans | NADPH Oxidases - metabolism | Human Umbilical Vein Endothelial Cells - immunology | NF-kappa B - metabolism | I-kappa B Proteins - metabolism | Dose-Response Relationship, Drug | C-Reactive Protein - metabolism | Transfection | I-kappa B Kinase - metabolism | Time Factors | Inflammation Mediators - metabolism | Superoxide Dismutase - metabolism | Recombinant Proteins - metabolism | Glutathione Peroxidase - metabolism | Human Umbilical Vein Endothelial Cells - drug effects | Anti-Inflammatory Agents - pharmacology | Glucagon-Like Peptide 1 - analogs & derivatives | Cells, Cultured | Glucagon-Like Peptide 1 - pharmacology | Antioxidants - pharmacology | NADPH Oxidase 2 | Protein Transport | Catalase - metabolism | NF-kappa B - genetics | Signal Transduction - drug effects | Serum Amyloid P-Component - metabolism | Oxidative Stress - drug effects | Liraglutide | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights